A Phase 1/3 Study of FPA144 Combined With Modified FOLFOX6 Versus Modified FOLFOX6 in Patients With Previously Untreated Advanced Gastric and Gastroesophageal Cancer (FIGHT)
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 22 Nov 2017
At a glance
- Drugs FPA 144 (Primary)
- Indications Gastric cancer; Gastrointestinal cancer
- Focus Adverse reactions
- Acronyms FIGHT
- Sponsors Five Prime Therapeutics
- 09 Nov 2017 Status changed from planning to not yet recruiting.
- 15 Aug 2017 New trial record
- 08 Aug 2017 According to a Five Prime Therapeutics media release, This safety trial will support the start of the global Phase 3 clinical trial.